In the News
OncLive
July 1, 2024
Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.
ESMO Daily Reporter
June 27, 2024
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting.
Mirror
June 14, 2024
The combination of two drugs used to boost immune response could shrink tumours in 60 per cent of patients, according to the new research by Anglia Ruskin University.
BioCentury
May 31, 2024
Several immuno-oncology mechanisms on display at this year’s ASCO help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.